Safe Administration

To date, there are no known adverse effects in humans due to the active ingredient concentrations in TauroLock™ when used as directed.

• The concentration of citrate in TauroLock™ (4 %) is safe and efficient according to the recommendation of the FDA, dated April 2000, (ref.: FDA Warning Letter, April 2000).
• TauroLock™ may cause mild hypocalcaemic symptoms if instillation is not done as slowly as directed.
• No risks compared to highly concentrated citrate-solutions (e.g. cardiac arrest,  arrhythmia, metallic taste, embolic complication).
• No risk of unwanted bleedings due to deficiency of calcium or due to the use of heparin. To avoid unwanted bleedings, TauroLock™ is free of heparin (HIT patient).
• TauroLock™ is biocompatible and nontoxic.
• In contrast to highly concentrated citrate there is no protein precipitation if using TauroLock™.